Biotech | December 13, 2021
Zydus to begin Phase II (a) clinical trial of ZYIL1 in Australia
It is a novel oral NLRP3 inflammasome inhibitor
It is a novel oral NLRP3 inflammasome inhibitor
KOREA PACK and concurrent event ICPI Week (Int’l Cosmetic and Pharmaceutical Industry Week) will be held as hybrid events in 2022
Under this scheme, the company will make a committed investment in plant and machinery, get incentives on incremental sales of pharmaceutical products
_256_384.jpg)
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
Saroglitazar Mg is an investigational compound in the USA, and is yet to be approved by the U.S. Food & Drug Administration (USFDA) or European Medicines Agency (EMA)
This is the fourth facility from the company to receive this registration
As part of the out-licensing deal with Tabuk, Biocon will develop and manufacture the products, and Tabuk will commercialise them
According to the Russian Direct Investment Fund (RDIF), the Russian Sputnik V and Sputnik Light vaccines have proven to be highly effective against all variants of SARC-Cov-2
Rad-G is a rugged, portable, handheld Masimo SET Measure-through Motion and Low Perfusion pulse oximeter and noninvasive respiration rate monitor
Subscribe To Our Newsletter & Stay Updated
